UK - GlaxoSmithKline, the pharmaceuticals giant, has suffered one of the biggest shareholder revolts in British corporate history following the rejection of a 'golden parachute' deal for chief executive Jean-Pierre Garnier.
The controversial deal, worth an estimated £22m, was defeated by shareholders following an annual general meeting yesterday, but only by a slim margin. Some 50.72% voted against the pay package, w...
To continue reading this article...
Join Professional Pensions
Become a Professional Pensions Lite Member today
In just a few clicks you can start your free Professional Pensions Lite membership for 12 months, providing you access to:
- Three complimentary articles per month covering the latest real-time news, analysis and opinion from the industry
- Receive important and breaking news stories via our two daily news alerts
- Hear from industry experts and other forward-thinking leaders
Are you a trustee, investment consultant or in-house pension and benefit scheme professional? You can apply for full complimentary access here
